SynthesisCurrent oncology reports2023
Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies.
Synthesis in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Potential Mechanism of Anti-tumor Effect of Trametes robiniophila Murr. (Huaier).Chinese journal of integrative medicine · 2026Review
- Natural panax notoginseng-derived nanovesicles trigger multiple cell death mechanisms and reprogram chemokine signaling to impede oral squamous cell carcinoma progression.Journal of nanobiotechnology · 2026Article
- Identification of regulatory candidate genes for Lentinula edodes pileus development based on transcriptome analysis.G3 (Bethesda, Md.) · 2026Article
- The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level.International journal of molecular sciences · 2026Review
- Modulation of gut microbiota and its metabolite Equol by Huaier granule suppresses hepatocellular carcinoma via the gut-liver axis.NPJ biofilms and microbiomes · 2026Article
- How Traditional Chinese Medicine Works: Biological Mechanisms and Clinical Evidence for Hepatocellular Carcinoma Treatment.Drug design, development and therapy · 2026Review
- When Nature Meets Oncology: Unraveling Herb-Drug Interactions in Cancer Therapy.International journal of molecular sciences · 2025Review
- Recent Advances in the Use ofPharmaceutics · 2025Review
- Mushroom Bioactive Molecules as Anticancerous Agents: An Overview.Food science & nutrition · 2025Review
- Multidisciplinary Integrative Medicine Approach for Cancer Patients: A Multicenter Retrospective Study.Nutrients · 2025Observational
- Review
- The Importance of Edible Medicinal Mushrooms and Their Potential Use as Therapeutic Agents Against Insulin Resistance.International journal of molecular sciences · 2025Review
- Symptom improvements and adverse effects with Reishi mushroom use: A Cross-Sectional survey of cancer patients.Integrative medicine research · 2024Article
- Medicinal Mushrooms in Metastatic Breast Cancer: What Is Their Therapeutic Potential as Adjuvant in Clinical Settings?Current issues in molecular biology · 2024Review
- Biological Activities of Secondary Metabolites from the Edible-Medicinal Macrofungi.Journal of fungi (Basel, Switzerland) · 2024Review
- The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer.Frontiers in pharmacology · 2024Review
- Pharmacodynamics of huaier aqueous extract against papillary thyroid carcinoma in vivo and in vitro.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPatients seek clinical guidance on mushroom supplements that can be given alongside conventional treatments, but most research on such fungi has been preclinical. The current systematic review focused on clinical studies of mushrooms in cancer care conducted in the past 10 years. We searched Medline (Ovid), Embase (Ovid), Scopus (Wiley), and Cochrane Library to identify all mushroom studies conducted in humans published from January 2010 through December 2020. Two authors independently assessed papers for inclusion. RECENT
findingsOf 136 clinical studies identified by screening 2349, 39 met inclusion criteria. The studies included 12 different mushroom preparations. A survival benefit was reported using Huaier granules (Trametes robiniophila Murr) in 2 hepatocellular carcinoma studies and 1 breast cancer study. A survival benefit was also found in 4 gastric cancer studies using polysaccharide-K (polysaccharide-Kureha; PSK) in the adjuvant setting. Eleven studies reported a positive immunological response. Quality-of-life (QoL) improvement and/or reduced symptom burden was reported in 14 studies using various mushroom supplements. Most studies reported adverse effects of grade 2 or lower, mainly nausea, vomiting, diarrhea, and muscle pain. Limitations included small sample size and not using randomized controlled trial design. Many of the reviewed studies were small and observational. Most showed favorable effects of mushroom supplements in reducing the toxicity of chemotherapy, improving QoL, favorable cytokine response, and possibly better clinical outcomes. Nevertheless, the evidence is inconclusive to recommend the routine use of mushrooms for cancer patients. More trials are needed to explore mushroom use during and after cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.